CClinicalTrials.gg
RecruitingNCT05132179Updated May 7, 2024

Treating Diabetic Foot Ulcers, Comparing Two Topical Antimicrobial Agents, Dakin´s and Prontosan

An interventional study of Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution in Diabetic Foot Ulcer, sponsored by Vastra Gotaland Region. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

202 Diabetic foot ulcers will be cleaned with either Hypochlorous Acid, HClO or Polyhexamethylene biguanide, PHMB twice a week until healed or 24 weeks. Primary objective is to find out if cleaning DFU with HClO is more effective in obtaining complete healing than PHMB.

Read the detailed description

202 persons with diabetes and diabetic foot ulcers, DFU will be randomized to treatment with either Hypochlorous Acid, HClO or Polyhexamethylene biguanide, PHMB. The study is double blind and controlled. The cleaning will be done as instruction for PHMB, twice a week until complete healing of the DFU or if not healed 24 weeks. Complete healing is defined as intact skin covering the place where there was an ulcer. Primary objective is time to healing, if cleaning DFU with HClO is more effective in obtaining complete healing of DFU than PHMB. Secondary objectives are to examine if HClO compared with PHMB differ when treating DFU with respect to: a. Proportion of DFU that heals within 12 weeks of treatment, b. The size of the DFU´s surface area over 24 weeks of treatment, c. The depth of the DFU over 24 weeks d. The use of antibiotics over 24 weeks of treatment, e. The quality of life using EQ-5D questionnaire. Explorative objectives are to examine if HClO compared with PHMB differ when treating DFU with respect to: a. Change in healing pattern (sub study in Västra Götaland), b. Change in microbiological variables (sub study in Västra Götaland), c. The quality of life using SF-12 questionnaire, d. Cost effectiveness and other health-economical aspects

02

Conditions studied

  • Diabetic Foot Ulcer

Keywords

  • Diabetic foot ulcer, DFU
  • Healing
  • Dakin´s solution
  • Prontosan Wound Irrigation Solution
  • Antibiotic consumption
  • Healing pattern
  • Microbiological variables
  • Cost-effectiveness
  • Diabetes type 1 and 2
  • Topical antimicrobial agent
  • Hypochlorous Acid
  • PHMB
  • Topical treatment
03

In context

Diabetic Foot

1,054 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

This study's planned enrollment of 202 is above the median of 60 across 826 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Vastra Gotaland Region is the lead sponsor of 267 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Informed consent obtained before trial-related activities,

  • Diabetes Mellitus type 1 or 2 or due to pancreatitis
  • Foot ulcer since 3 weeks or more
  • Ulcer surface area 9 mm2 or more
  • Age 18 years old or more

Exclusion Criteria:

  • Persons in need of intensive care or dialysis
  • Persons in need of vascular intervention, critically impaired circulation (toe-pressure \< 30 mm Hg)
  • Event of myocardial infarction or stroke during the last three months
  • Debut of atrial fibrillation or heart failure during the last three months
  • Current treatment of malignancy
  • Treatment with corticosteroids with a dose corresponding to 50 mg Prednisolon
  • Severe wound infection according to International Working Group of Diabetic Foot, IWGDF at least two of following signs: body temperature \<36 C or >38 C, heart rate >90/minute, respiration rate >20/minute, LPK >12x10\^9/L
  • Planned changed residence in the coming 12 months requiring change of clinic for wound treatment during the follow-up time
  • Age under 18 years old
  • Diabetes of MOODY type
  • Current known pregnancy or planned pregnancy next 26 weeks
  • Participation in another clinical trial evaluating any treatment
  • Other reasons judged by the investigator that the patient is unsuitable for participation in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
202 participants (estimated)

Study arms

  • Active comparator
    HOCl arm

    Dakin´s Solution, with the active substance Hypochlorous Acid, HOCl was first invented 1915 for use on infected war wounds. The DFU will be cleaned with HOCl twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.

    Drug: Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution

  • No intervention
    PHMB arm

    Prontosan, with the active substance PHMB, is recommended by 19 out of 21 regions in Sweden, for cleaning DFU. The DFU will be cleaned with PHMB twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.

Interventions

  • DrugDakins Full Strength Solution, 0.5% Topical Solution, HOCl solution

    Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.

    Also known as: Dakins

06

What researchers measure

Primary outcomes

  1. Time to healing

    The primary efficacy analysis of difference in time to healing from randomisation up to 24 weeks between the two randomised groups. Analysis will be performed using Cox regression. The healing date will be defined as the first visit when the ulcer is fully covered with skin.

    Time frame: 24 weeks

Secondary outcomes

  1. Proportion of DFU that heals within 12 weeks of treatment

    Difference in proportion healed DFU between groups at week 12 will be estimated using Fisher´s exact test

    Time frame: 12 weeks

  2. Change of DFU´s surface area

    The size of surface area measured with a mm ruler in photo of the DFU. The surface area of The DFU will be measured weekly for 24 weeks or until healed from weekly photo with a mm ruler in the photo. The calculation of the area will be done by a person not involved in the treatment. For each participants and time point, the percentage change of the ulcer size (area and volume) will be calculated in relation to randomisation. For each group (HOCl and PHMB, respectively), the average change in ulcer size (area and volume) will be calculated, whereafter any difference between the two groups will be examined for statistical significance.

    Time frame: 24 weeks

  3. Change of diabetic foot ulcer´s, DFU´s, depth

    The depth of diabetic foot ulcer measured with digital pair of calipers weekly for 24 weeks or until healed. For each participant and time point, the percentage change of the ulcer size (area and volume) will be calculated in relation to the date of randomisation. For each group (HOCl and PHMB, respectively), the average change in ulcer size (area and volume) will be calculated, whereafter any difference between the two groups will be examined for statistical significance.

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • NU sjukvarden
    Uddevalla, Trollhattan s-46185, Sweden
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05132179
Lead sponsor
Vastra Gotaland Region
Responsible party
Marcus Lind (Professor, consultant Endocrinology, Vastra Gotaland Region) — Principal investigator
First posted
Nov 24, 2021
Start date
Feb 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 7, 2024

Study contacts

Karin Bergqvist, MD
Contact
karin.bergqvist@vgregion.se
+46730961700
Marcus Lind, Prof
Contact
lind.marcus@telia.com
+46700824239
Marcus Lind, Prof
principal investigator · University of Gothenburg, Sahlgrenska Academy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion